Asunto(s)
Antibacterianos/farmacología , Encéfalo/enzimología , Inhibidores Enzimáticos/farmacología , Macrólidos , Esfingomielina Fosfodiesterasa/antagonistas & inhibidores , Animales , Antiinflamatorios no Esteroideos/farmacología , Bacillus cereus/efectos de los fármacos , Bacillus cereus/enzimología , Encéfalo/efectos de los fármacos , Carragenina , Dinoprostona/biosíntesis , Edema/inducido químicamente , Edema/tratamiento farmacológico , Cinética , Lipopolisacáridos/farmacología , Micromonospora/metabolismo , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Ratas , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/enzimologíaRESUMEN
Scyphostatin is a specific inhibitor for mammalian neutral magnesium-dependent sphingomyelinase with a fifty percent inhibition concentration (IC50) value of 1.0 microM. When used to inhibit lysosomal acid sphingomyelinase, an approximately 50-fold greater concentration is required. In human peripheral monocytes, the compound inhibits bacterial lipopolysaccharide (LPS)-induced prostaglandin E2 production and LPS-induced interleukin-1beta production with IC50 values of 0.8 microM and 0.1 microM, respectively. In rat, p.o. administration of the compound has also been shown to inhibit carrageenin-induced paw edema. Thus, it is hoped that utility of scyphostatin as a pharmacological tool will contribute to our understanding of the role of ceramide in the cellular inflammation process.